Alpha Teknova SEC Filings

Alpha Teknova reported first quarter 2026 revenue of $11.1 million, up 13% from $9.8 million a year earlier, driven by growth in both major product lines. Lab Essentials revenue rose to $8.4 million, while Clinical Solutions nearly doubled to $2.1 million.

Gross margin improved to 34.2% from 30.7% as gross profit increased to $3.8 million. Operating expenses were $8.1 million, resulting in a net loss of $4.6 million, or $0.08 per share, similar to the prior year. Adjusted EBITDA was negative $2.0 million and Free Cash Outflow was $3.6 million, both better than 2025 levels.

The company ended the quarter with $17.8 million in cash and short-term investments and $13.2 million of total borrowings. Teknova reaffirmed its 2026 outlook for revenue of $42–44 million and expects full-year Free Cash Outflow of less than $10 million. The board also approved a refreshed Code of Business Conduct and Ethics focused on updates, clarifications, and administrative improvements.

Alpha Teknova, Inc. will hold its 2026 annual shareholder meeting in person at its Hollister, California offices on June 1, 2026 at 12:00 p.m. Pacific Time. Stockholders of record as of April 2, 2026, when 53,610,200 common shares were outstanding, may vote.

Investors are asked to elect three Class II directors (Irene Davis, J. Matthew Mackowski, and Brett Robertson) for terms running until the 2029 meeting and to ratify Grant Thornton LLP as independent auditor for the year ending December 31, 2026. A plurality vote elects directors, while auditor ratification requires a majority of votes present and entitled to vote.

The company is a Nasdaq “controlled company” because Telegraph Hill–affiliated funds hold a majority of the voting power, allowing exemptions from some independence requirements. Independent directors receive a $40,000 annual cash retainer plus committee fees and annual option grants, with overall board pay capped per the 2021 Equity Incentive Plan.

Alpha Teknova reported 2025 audit fees of $620,172 and audit-related fees of $12,840 for Grant Thornton. Executive pay for 2025 included salary, annual incentives, and equity awards for the CEO, CFO, and General Counsel, reflecting a mix of cash and long-term incentives.

Terrill Damon reported acquisition or exercise transactions in this Form 4 filing.

Alpha Teknova, Inc. reported that its General Counsel and Chief Compliance Officer, Terrill Damon, received a grant of non-qualified stock options covering 148,000 shares on February 15, 2026. The options were recorded at a price of $0.0000 per share in the filing.

According to the disclosure, all 148,000 options are held directly by Damon. A footnote explains that the shares underlying the option will vest in 48 equal monthly installments on the same day of each month after February 15, 2026, gradually becoming exercisable over four years.

Alpha Teknova, Inc. Chief Financial Officer Lowell Matthew reported two equity transactions. On March 6, 2026, he made an open-market purchase of 40,000 shares of common stock at a weighted average price of $2.19 per share, bringing his directly held common stock to 168,376 shares.

On February 15, 2026, he also received a grant of 171,000 non-qualified stock options with an exercise price of $0.00 per share. These options vest in 48 equal monthly installments starting on February 15, 2026.

Alpha Teknova, Inc. President and CEO Stephen Gunstream reported two equity transactions. On March 6, 2026, he made an open-market purchase of 26,000 shares of common stock at a weighted average price of $2.1462 per share, bringing his direct common stock holdings to 269,497 shares. Separately, on February 15, 2026, he received a grant of 429,000 non-qualified stock options with an exercise price of $0.00 per option. These options vest in 48 equal monthly installments on the same day of each month following the February 15, 2026 grant date.

Alpha Teknova, Inc. is a specialist manufacturer of custom reagents used in developing novel therapies, vaccines, and molecular diagnostics for more than 3,000 life science customers. It focuses on fast, made‑to‑order production from discovery through commercialization, with most products made in Hollister, California.

The company organizes its portfolio into Lab Essentials and Clinical Solutions. In 2025, Lab Essentials contributed 76.6% of revenue, largely from catalog items, while higher‑value Clinical Solutions contributed 18.9%, mostly custom GMP‑grade products. About 24% of revenue came from cell and gene therapy customers, a key long‑term growth focus.

Teknova reported a 2025 net loss of $17.3 million, an improvement from a $26.7 million net loss in 2024, while continuing to invest in capacity, automation, and quality systems. The business highlights high customer loyalty, with roughly 95% annual retention among larger accounts, rapid lead times for custom products, and strong exposure to growing markets like mRNA, molecular diagnostics, and genomics, balanced by risks around funding cycles, competition, supply chain concentration, and regulatory demands.

Alpha Teknova, Inc. reported moderate growth and much stronger margins for 2025 while remaining unprofitable. Total revenue for 2025 was $40.5 million, up 7% from $37.7 million, with fourth-quarter revenue of $10.0 million, up 8% year over year.

Full-year gross margin improved to 33.2% from 19.2%, helped by higher revenue and manufacturing efficiency gains, and operating expenses fell to $30.4 million from $33.4 million. Net loss narrowed to $17.3 million (negative $0.32 per share) from $26.7 million, and Adjusted EBITDA improved to negative $6.7 million from negative $14.5 million.

Free Cash Flow for 2025 was negative $9.8 million, better than negative $13.5 million in 2024 and ahead of the company’s prior target. Teknova ended 2025 with $21.3 million in cash and short-term investments and $13.2 million of gross debt, and guided 2026 revenue to $42–44 million with expected Free Cash Outflow of less than $10 million.

Alpha Teknova (TKNO) reported Q3 2025 results. Revenue was $10.5 million, up 9.2% year over year. Gross margin improved to 30.7% from 0.9% a year ago, reflecting the absence of prior-year inventory charges. Operating loss narrowed to $4.0 million, and net loss was $4.3 million (net loss per share of $0.08).

For the first nine months, revenue reached $30.5 million (up 7.2%) with a 33.4% gross margin. General and administrative costs fell year over year, contributing to a smaller operating loss. Cash and cash equivalents plus short‑term investments totaled $22.1 million as of September 30, 2025, within $29.6 million of net working capital.

The company’s amended credit facility totals $28.245 million (term loan and revolver) and includes covenants, including a minimum trailing‑twelve‑month net revenue of $39.0 million for the period ending December 31, 2025, and a minimum cash requirement of $8.0 million. Shares outstanding were 53,529,174 as of November 5, 2025.